Market Overview

ACETO's Rising Pharma to Launch Generic of Cleocin Pediatric

Related ACET
Top 4 Small-Cap Stocks In The Chemicals-Major Diversified Industry With The Highest EPS Growth Forecast For Next 5 Years
ACETO Subsidiary, Rising Pharmaceuticals, Acquires Three FDA-Approved Ophthalmic ANDAs From Nexus Pharmaceuticals

ACETO Corporation (Nasdaq: ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, has launched the generic version of the 75mg/*5mL strength of Clindamycin Palmitate Hydrochloride for Oral Solution, USP (Pediatric), an FDA approved generic version of Pfizer Inc.'s Cleocin Pediatric®. According to IMS Health data, U.S. market sales for Clindamycin Palmitate Hydrochloride, which is an antibiotic that is used to treat serious infections caused by bacteria, were approximately $59 million for the twelve months ended June 30, 2012.

Posted-In: News FDA


Related Articles (ACET)

View Comments and Join the Discussion!

Get Benzinga's Newsletters